Marginal Donor Use in Patients Undergoing Heart Transplantation With Left Ventricular Assist Device Explantation.
The use of continuous flow (CF) left ventricular assist devices (LVAD) as a bridge to orthotopic heart transplantation (OHT) has increased. This study examined survival outcomes after CF-LVAD explantation and OHT using marginal donors. Adults undergoing OHT with or without LVAD explant using marginal donors between 2007 and 2014 were identified in the Scientific Registry for Transplant Recipients database. A previously validated donor risk score was used to define marginal donors. Patients were stratified into four groups based on utilization of a marginal donor with or without LVAD explantation at OHT. Graft survival was analyzed at 1 and 5 years. Overall, 7,798 patients with OHT were analyzed. Whereas 1,862 patients (24%) underwent direct OHT utilizing marginal donors, only 626 patients (30% [group A]) underwent OHT with LVAD explant (HeartMate II [Thoratec, Pleasanton, CA], n =581, 93%; HVAD [HeartWare, Framingham, MA], n = 45, 7%) and 1,236 (70%) underwent direct OHT (group B). Standard donors were utilized for 2,334 patients with CF-LVAD explant (group C), and 3,602 patients underwent direct OHT (group D). Utilization of marginal donors in patients undergoing LVAD explantation was associated with decreased posttransplant graft survival (p < 0.001). After adjusting for recipient age, sex, listing status at OHT, body mass index, creatinine, and duration of LVAD support, Cox regression analysis found that patients bridged with LVADs, recipients receiving transplants from marginal donors, recipients with highest age and body mass index, and highest creatinine were at increased risk of graft failure (all p < 0.01). Utilization of marginal donors in patients undergoing CF-LVAD explantation and OHT is associated with reduced early and late graft survival. These findings support cautionary use of marginal donors in patients bridged with CF-LVAD.